All In Biotech

Drug Trial Radar · NCT00934492

Cotrimoxazole Prophylaxis in Severely Malnourished Children

Randomized, Placebo Controlled Trial of Cotrimoxazole Prophylaxis Amongst HIV-uninfected Children With Severe Malnutrition

Last checked: Nov 19, 2026Latest source record: Aug 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,781 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,781

Actual

Start

Nov 2009

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kenya Medical Research Institute
First posted
Jul 8, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 2 months, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial aims to test the hypothesis that mortality among Kenyan children with severe malnutrition following initial stabilisation is due to ongoing vulnerability to infectious disease, and that long term daily co-trimoxazole prophylaxis will reduce mortality. The objective is to conduct a randomized, double blind, placebo-controlled trial of cotrimoxazole prophylaxis for 6 months among HIV-uninfected children with severe malnutrition following stabilization. The primary outcome will be survival at one year. Secondary outcomes are toxicity, growth, the frequency and causes of hospitalisation and microbial resistance to antibiotics. Cotrimoxazole has striking protective efficacy against mortality among children with HIV, despite not altering the underlying immune deficiency. It is hypothesised that co-trimoxazole prophylaxis will have a similar effect in children immunocompromised because of severe malnutrition. Worldwide, severe malnutrition is commoner than HIV in childhood and co-trimoxazole is cheap and widely available, making it easily translatable to policy.

Conditions

  • Nutrition Disorders
  • Life-threatening Infection

Interventions

  • Cotrimoxazole dispersible tabletDrug

    Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.

  • Placebo dispersible tabletDrug

    Placebo dispersible tablets 120/240mg daily for six consecutive months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 12 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Mbagathi District Hospital

    Nairobi, Kenya

  • KEMRI/Wellcome Trust Research Programme

    Kilifi, Coast, Kenya

  • Malindi District Hospital

    Malindi, Coast, Kenya

  • Coast Provincial General Hospital

    Mombasa, Coast, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.